US RAC Review Questions RAPS Modules 2024.
In which situation is an IND not required?
A) You intend to conduct a clinical trial with an investigational new drug
B) You intend to conduct a clinical trial with an approved drug to support a marketing application for a new indication
C) You i...
in the clinical development plan for an investigat
a sponsor must report an unexpected fatal or life
Geschreven voor
RAC.
RAC.
Verkoper
Volgen
ROSEGRADES
Ontvangen beoordelingen
Voorbeeld van de inhoud
US RAC Review Questions RAPS Modules 2024.
In which situation is an IND not required?
A) You intend to conduct a clinical trial with an investigational new drug
B) You intend to conduct a clinical trial with an approved drug to support a marketing application for a new indication
C) You intend to collect blood samples from subjects to look for biomarkers or pharmacogenetic information
D) You intend to conduct a clinical trial using 2 of your approved drugs in a new combination - CORRECT ANSWER C) You intend to collect blood samples from subjects to look for biomarkers or pharmacogenetic information
In the clinical development plan for an investigational antihypertensive drug, which of the following studies would typically be conducted first:
A) 1 month repeat dose toxicology study
B) Single dose escalation PK study in healthy volunteers
C) Multiple dose PK study in healthy volunteers
D) Single dose escalation study in hypertensive patients - CORRECT ANSWER B) Single dose escalation PK
study in healthy volunteers
A sponsor must report an unexpected, fatal or life-threatening experience believed to be associated with an unapproved drug/biologic:
A) to FDA, investigators and IRBs within 7 calendar days
B) to FDA and investigators within 7 calendar days
C) to FDA within 14 calendar days D) to FDA and investigators within 7 working days - CORRECT ANSWER B) to FDA and investigators within 7 calendar days
Which of the following is a covered study as defined under Financial Disclosure regulations:
A) Phase I dose escalation study
B) Phase I/II Pharmacokinetic Study
C) A large open label safety study conducted at a large number of study sites
D) Phase III pivotal study - CORRECT ANSWER D) Phase III pivotal study
Your company is developing a product to treat a serious and life threatening disease. A clinically meaningful, well established primary endpoint will be used in the pivotal studies. Which regulatory strategy might you select prior to commencing Phase 3 studies?
A) Request Special Protocol Assessment
B) Request Fast Track Designation
C) Request Priority Review
D) Approval under Subpart H, Accelerated Approval of New Drugs for Serious or Life Threatening Illnesses - CORRECT ANSWER A) Request Special Protocol Assessment
As a regulatory affairs professional, you are responsible for developing the content of an information package for a Type B meeting with FDA. Your primary objective is to:
A) Reach consensus on content from contributing team members
B) Ensure content is sufficient to support meeting objective(s) and questions to FDA
C) Provide appropriate preclinical summary
D) Provide appropriate clinical summary - CORRECT ANSWER B) Ensure content is sufficient to support meeting objective(s) and questions to FDA
You, a regulatory affairs professional, are assessing the information to be submitted in support of a marketing application for a new dosage form for a listed drug. You lack right of reference to one key preclinical report. Which type of application will you prepare for submission? A) 505 (b) (1)
B) 505 (b) (2)
C) 505 (j)
D) PMA - CORRECT ANSWER B) 505 (b) (2)
8) If FDA were to invoke the Application Integrity Policy, which of the following is a possible outcome?
A) Defer review of pending application(s)
B) "File" a marketing application at the 60 day review
C) Grant a waiver or deferral for pediatric clinical study
D) Approve a marketing application - CORRECT ANSWER A) Defer review of pending application(s)
9) Which of the following supplements to an approved NDA/BLA must be approved by FDA prior to distributing product made using the change?
A) Make change(s) to comply with USP
B) Change in the technical grade of an excipient, same
specifications and use
C) Add a warning statement to prescribing information
D) Process change outside the validated range - CORRECT ANSWER D) Process change outside the validated range
10) Which of the following products would not be regulated by CDER?
A) Therapeutic proteins
B) Vaccines
C) Chemically synthesized small molecules
D) Monoclonal antibodies - CORRECT ANSWER B) Vaccines
Voordelen van het kopen van samenvattingen bij Stuvia op een rij:
√ Verzekerd van kwaliteit door reviews
Stuvia-klanten hebben meer dan 700.000 samenvattingen beoordeeld. Zo weet je zeker dat je de beste documenten koopt!
Snel en makkelijk kopen
Je betaalt supersnel en eenmalig met iDeal, Bancontact of creditcard voor de samenvatting. Zonder lidmaatschap.
Focus op de essentie
Samenvattingen worden geschreven voor en door anderen. Daarom zijn de samenvattingen altijd betrouwbaar en actueel. Zo kom je snel tot de kern!
Veelgestelde vragen
Wat krijg ik als ik dit document koop?
Je krijgt een PDF, die direct beschikbaar is na je aankoop. Het gekochte document is altijd, overal en oneindig toegankelijk via je profiel.
Tevredenheidsgarantie: hoe werkt dat?
Onze tevredenheidsgarantie zorgt ervoor dat je altijd een studiedocument vindt dat goed bij je past. Je vult een formulier in en onze klantenservice regelt de rest.
Van wie koop ik deze samenvatting?
Stuvia is een marktplaats, je koop dit document dus niet van ons, maar van verkoper ROSEGRADES. Stuvia faciliteert de betaling aan de verkoper.
Zit ik meteen vast aan een abonnement?
Nee, je koopt alleen deze samenvatting voor €13,87. Je zit daarna nergens aan vast.
